摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(3,4-dichlorobenzyl)-2-methylthio-4-pyrimidone | 63204-35-3

中文名称
——
中文别名
——
英文名称
5-(3,4-dichlorobenzyl)-2-methylthio-4-pyrimidone
英文别名
2-methylthio-5-(3,4-dichlorobenzyl)pyrimid-4-one;5-(3,4-dichloro-benzyl)-2-methylsulfanyl-3H-pyrimidin-4-one;5-[(3,4-dichlorophenyl)methyl]-2-methylsulfanyl-1H-pyrimidin-6-one
5-(3,4-dichlorobenzyl)-2-methylthio-4-pyrimidone化学式
CAS
63204-35-3
化学式
C12H10Cl2N2OS
mdl
——
分子量
301.196
InChiKey
CUDPTJIZUFTCSL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.44±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    18
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    66.8
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • 2-Pyridylaminoakylamino-4-pyrimidones useful as histamine H.sub.1
    申请人:Smith Kline & French Laboratories Limited
    公开号:US04547506A1
    公开(公告)日:1985-10-15
    Pyridine derivatives are disclosed which are useful as histamine H.sub.1 -antagonists.
    已披露了作为组胺H.sub.1-拮抗剂有用的吡啶衍生物
  • 4-Pyrimidones compositions, and methods of use
    申请人:SmithKline & French Laboratories Limited
    公开号:US04159329A1
    公开(公告)日:1979-06-26
    The compounds are substituted isocytosines which are histamine H.sub.2 -antagonists. Two specific compounds of the present invention are 2-[2-(5-methyl-4-imidazolylmethylthio)-ethylamino]-5-(3-methoxybenzyl)-4-p yrimidone and 2-[2-(5-methyl-4-imidazolylmethylthio)ethylamino]-6-benzyloxy-4-pyrimidone .
    这些化合物是取代的异胞嘧啶,它们是组胺H.sub.2-拮抗剂。本发明的两种具体化合物是2-[2-(5-甲基-4-咪唑基甲基)-乙基基]-5-(3-甲氧基苯基)-4-嘧啶酮和2-[2-(5-甲基-4-咪唑基甲基)乙基基]-6-苄氧基-4-嘧啶酮。
  • Substituted 4-pyrimidone compounds, compositions and methods of use
    申请人:Smith Kline & French Laboratories Limited
    公开号:US04218452A1
    公开(公告)日:1980-08-19
    The compounds are substituted isocytosines which are histamine H.sub.2 -antagonists. Two specific compounds of the present invention are 2-[2-(5-methyl-4-imidazolylmethylthio)ethylamino]-5-(3-methoxybenzyl)-4-py rimidone and 2-[2-(5-methyl-4-imidazolylmethylthio)ethylamino]-5-benzyloxy-4-pyrimidone .
    这些化合物是取代的异胞嘧啶,是组胺H.sub.2-拮抗剂。本发明的两种特定化合物是2-[2-(5-甲基-4-咪唑甲基基)乙基基]-5-(3-甲氧基苯基)-4-吡咯酮和2-[2-(5-甲基-4-咪唑甲基基)乙基基]-5-苄氧基-4-吡咯酮
  • Iso(thio)ureas, processes for their preparation and compositions containing them
    申请人:SMITH KLINE & FRENCH LABORATORIES LIMITED
    公开号:EP0007232A1
    公开(公告)日:1980-01-23
    Isoureas and isothioureas which are histamine H2- antagonists and also have histamine H1-antagonist activity and antiinflammatory activity having the structure in which R' and R2 are hydrogen, lower alkyl, or together with the carbon and two nitrogen atoms shown form a dihydroimidazolyl or tetrahydropyrimidyl group, Y is sulphur or oxygen, n is from 3 to 8, X is oxygen or sulphur, Z is hydrogen or lower alkyl, A is C1-C3 alkylene or -(CH2)pW(CH2)q- where W is oxygen or sulphur and the sum of p and q is 1 to4, and B is methyl, cycloalkyl, heteroaryl, aryl or, when A is alkylene, hydrogen, are prepared by a process in which a compound of structure where D is HY- or a leaving group is reacted with: (a) when D is HY-, an isothiourea where A is lower alkyl or aryl (lower alkyl), or a cyanamide R1HNCN or a carbodiimide R1N=C=NR2 or (b) when D is a leaving group, a urea or thiourea or, when Y is oxyen a compound of structure where G is a lower alkylthio, chlorine, bromine or NO2NH-, is reacted with an isothiourea of Structure
    类和异硫脲类是组胺 H2-拮抗剂,也具有组胺 H1-拮抗剂活性和抗炎活性,其结构为 其中 R' 和 R2 为氢、低级烷基或与所示的碳原子和两个氮原子一起形成二氢咪唑基或四氢嘧啶基,Y 为或氧,n 为 3 至 8,X 为氧或,Z 为氢或低级烷基、A 为 C1-C3 亚烷基或-(CH2)pW( )q-,其中 W 为氧或,p 和 q 之和为 1 至 4,B 为甲基、环烷基、杂芳基、芳基或(当 A 为亚烷基时)氢,通过以下工艺制备结构如下的化合物 其中 D 为 HY- 或离去基团,并与之反应: (a) 当 D 为 HY- 时,异硫脲 其中 A 为低级烷基或芳基(低级烷基),或氰胺 R1HNCN 或碳化二亚胺 R1N=C=NR2 或 (b) 当 D 为离去基团时,硫脲 或当 Y 为氧烯时,结构如下的化合物 其中 G 为低级烷基、或 NO2NH- 时,与结构式如下的异硫脲反应
  • Pyrimidinone derivatives, processes for preparing them and pharmaceutical compositions containing them
    申请人:SMITH KLINE & FRENCH LABORATORIES LIMITED
    公开号:EP0013071A1
    公开(公告)日:1980-07-09
    The invention provides new histamine H2- antagonist compounds of Structure 1 in which R' is hydrogen, lower alkyl, lower alkoxy, hydroxy, halogen, trifluoromethyl, nitro, amino, lower alkylamino, lower alkanoylamino, di(lower alkyl)amino or cyano; R2 is in the 3-, 4- or 5- position and is hydrogen, or R2 is lower alkyl substituted by amino, lower alkylamino, di(lower alkyl)amino, N-piperidino or N-pyrollidino, or R2 is ethoxy or propoxy w-substituted by amino, lower alkylamino, di(lower alkyl)amino, N-piperidino or N-pyrollidino; Y is methylene or oxygen and X is methylene or sulphur provided that one or two of the groups X and Y is methylene; Z is hydrogen or lower alkyl; A is C1-C5 alkylene or-(CH2)pW-(CH2)q-where W is oxygen or sulphur and p and q are such that their sum is from 1 to4, and B is hydrogen, methyl, C3-C6 cycloalkyl, a heteroaryl group optionally substituted by one or more of the groups lower alkyl, lower alkoxy, halo, hydroxy and amino, or B is a naphthyl, 6-(2,3-dihydro-1,4-benzodioxinyl), a 4- or 5-(1,3-benzodioxolyl) group, or a phenyl group optionally substituted with one or more lower alkyl, lower alkoxy, halogen, aryl(lower alkoxy), hydroxy, lower alkoxy-lower alkoxy, trifluoromethyl, di(lower alkyl)amino, phenoxy, halophenoxy, lower alkoxyphenoxy, phenyl, halophenyl or lower alkoxyphenyl groups and pharmaceutical compositions containing them. A compound of Structure 1 can be prepared by reacting a compound of Structure 3 in which Q is nitroamino, loweralkylthio, benzylthio or halogen with an amine of Structure 2, in which R3 is in the 3-, 4- or 5p position and is hydrogen, lower alkyl substituted by a group R4, or is R4CH2CH2O-or R4CH2CH2CH2O-, where R' is di(lower alkyl)amino, N-piperidino, N-pyrrollidino, a protected amino group or a protected lower alkylamino group, and where necessary any amino-protecting group present in the substituent R3 is removed.
    本发明提供了结构 1 的新型组胺 H2- 拮抗剂化合物 其中R'是氢、低级烷基、低级烷氧基、羟基、卤素、三甲基、硝基、基、低级烷基基、低级烷酰基、二(低级烷基)基或基;R2 位于 3-、4-或 5-位且为氢,或 R2 为被基、低级烷基基、二(低级烷基)基、N-哌啶基或 N-吡咯烷基取代的低级烷基,或 R2 为被基、低级烷基基、二(低级烷基)基、N-哌啶基或 N-吡咯烷基取代的乙氧基或丙氧基;Y 为亚甲基或氧,X 为亚甲基或,条件是 X 和 Y 中的一个或两个基团为亚甲基;Z 为氢或低级烷基;A是C1-C5亚烷基或-(CH2)pW-( )q-其中W是氧或,p和q的和为1至4,B是氢、甲基、C3-C6环烷基、任选被一个或多个基团低级烷基、低级烷氧基、卤代、羟基和基取代的杂芳基,或者B是基、6-(2,3-二氢-1,4-苯并二噁烷基)、4-或5-(1、3-苯并二恶茂基)基团,或任选被一个或多个低级烷基、低级烷氧基、卤素、芳基(低级烷氧基)、羟基、低级烷氧基-低级烷氧基、三甲基、二(低级烷基)基、苯氧基、卤代苯氧基、低级烷氧基苯氧基、苯基、卤代苯基或低级烷氧基苯基基团取代的苯基基团以及含有它们的药物组合物。结构 1 的化合物可通过结构 3 的化合物(其中 Q 为硝基基、低级烷基、苄基或卤素) 与结构 2 的胺反应制备,其中 R3 位于 3-、4-或 5p 位,是氢、被基团 R4 取代的低级烷基或 R4 O- 或 R4 O-,其中 R' 是二(低级烷基)基、N-哌啶基、N-吡咯烷基、受保护的基或受保护的低级烷基基,必要时去除取代基 R3 中存在的任何基保护基。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫